Transthyretin-mediated amyloid cardiomyopathy (attr-CM)

Clinical trials for Transthyretin-mediated amyloid cardiomyopathy (attr-CM) explained in plain language.

Never miss a new study

Get alerted when new Transthyretin-mediated amyloid cardiomyopathy (attr-CM) trials appear

Sign up with your email to follow new studies for Transthyretin-mediated amyloid cardiomyopathy (attr-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1 Completed 3

New drug eplontersen tested for Long-Term safety in heart disease patients

Disease control By invitation only

This study is checking the long-term safety of a drug called eplontersen in people with ATTR-CM, a heart condition caused by abnormal protein buildup. About 1400 adults who completed earlier studies will receive eplontersen injections. Researchers will monitor side effects, kidne…

Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)

Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:08 UTC

Transthyretin-mediated amyloid cardiomyopathy (attr-CM)

Get alerted when new Transthyretin-mediated amyloid cardiomyopathy (attr-CM) trials appear

New drug eplontersen tested for Long-Term safety in heart disease patients